Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference

HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, being held virtually on October 8-9, 2026.

The fireside chat will be held on Thursday, October 8, 2026, at 9:30 AM ET. A live webcast of the presentation will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the live event.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:

Lindsey Trickett

Head of Investor Relations and Corporate Communications

Email: [email protected]

Tel: +1 (628) 241-0071

SOURCE Compugen Ltd.

Share this article

- Chief Medical Officer Dr. Sam Barone to join the Emerging Innovations in Retinal Therapies panel; Company to present an update on MOGENRY® in the Retina Drug Delivery & New Targets Showcase at Eyecelerator 2026

- Four-year REMAIN data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa and a scientific poster on dry AMD to be presented at the AAO 2026 Annual Meeting, October 8–13, 2026, in New Orleans, Louisiana

DALLAS, Oct. 6, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that its optogenetics gene therapy (MOGENRY, MCO-010) will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) 2026 annual meeting taking place October 8–13, 2026, in New Orleans. Additionally, the company will participate in Eyecelerator@AAO 2026 with a company presentation and panel participation. Eyecelerator brings together ophthalmic innovators, industry leaders, clinicians, and investors to accelerate the development of new therapies and technologies in eye care. The AAO Annual Meeting is the world's largest gathering of ophthalmologists and eye care professionals.

Presentation Details:

Eyecelerator 2026, Ernest N. Morial Convention Center

Panel: Emerging Innovations in Retinal Therapies

Panelist: Sam Barone, MD, Chief Medical Officer

Date & Time: Thursday, October 8, 2026, 10:45–11:30 AM CT

Location: La Nouvelle Ballroom C

Company Presentation: Retina Drug Delivery & New Targets Showcase

Presenter: Paul Hallen, Chief Operating Officer

Date & Time: Thursday, October 8, 2026, 1:00–1:05 PM CT

Location: Rooms 252–254

AAO 2026 Annual Meeting, Ernest N. Morial Convention Center

Presentation: Lasting Vision Improvement in Retinitis Pigmentosa: REMAIN 4-Year Study Data From the RESTORE Phase 2b/3 Trial of MCO-010 Optogenetic Therapy

Session: PA044

Presenter: Kenneth C. Fan, MD

Date & Time: Sunday, October 11, 2026, 11:42–11:49 AM CT

Location: Rooms 255–257

Scientific Poster: Vision Improvement in Dry AMD With Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 RCT

Session: PO624

Presenter: David S. Boyer, MD

Availability: On demand

During the panel, Dr. Barone will join fellow industry leaders to discuss emerging approaches in retinal therapeutics, including the potential of mutation-agnostic optogenetic gene therapy for patients with advanced retinal degeneration. In the Showcase presentation, Mr. Hallen will provide an update on Nanoscope's progress toward potential global approval of its lead asset, MOGENRY® (sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company's Biologics License Application (BLA), and Japan New Drug Application (JNDA), currently under FDA and PMDA review respectively. At AAO 2026, Dr. Fan will present four-year data from the REMAIN study of patients treated in the RESTORE Phase 2b/3 trial, highlighting the durability of vision improvement with MCO-010 in retinitis pigmentosa. Dr. David S. Boyer will also present a scientific poster, available on demand, on vision improvement with sonpiretigene isteparvovec in dry AMD from the first direct-to-Phase 2 randomized controlled trial. Members of the Nanoscope leadership team will be available to meet with retina specialists, investors, and potential partners throughout Eyecelerator and AAO 2026.

Nanoscope team members will be available at Booth 2564 for the duration of the AAO conference.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)

Nanoscope's multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope's Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows. MOGENRY is under review by the FDA for the treatment of RP with severe vision loss and under priority review by the PMDA and MHLW for the treatment of IRDs in Japan. The 2026 Nobel Prize in Physiology or Medicine was recently awarded to the three scientists who pioneered optogenetics, the scientific foundation that Nanoscope's development programs, including MOGENRY, are built upon.

About Nanoscope Therapeutics

- Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company's BLA for MOGENRY, and the PMDA has accepted for priority review the Company's NDA for MOGENRY for the treatment of IRDs in Japan. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).

Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn.

Contact:

Nanoscope Therapeutics, Inc

(817) 857-1186

SOURCE Nanoscope Therapeutics

Share this article

e‑STORAGE to Supply and Commission 100 MW/200 MWh Battery Storage System for OX2 in New South Wales

KITCHENER, ON, Oct. 6, 2026 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e‑STORAGE, its energy storage solutions business, has signed an agreement to supply and commission a 100 MW/200 MWh battery energy storage system (BESS) for OX2's Muswellbrook Solar Farm and Battery, a solar-plus-storage project in New South Wales, Australia. Shipments are scheduled to begin in Q3 2027, with commercial operation targeted for Q3 2028. The battery cells and SolBank system will be produced in-house at Canadian Solar's manufacturing facilities, giving the customer end-to-end supply chain visibility and ensuring strict quality control across the product.

e‑STORAGE will deliver an integrated solution built on SolBank 3.0 battery containers, paired with Power Conversion Systems (PCS), plant controls, and the Company's proprietary EQ-S Energy Management System (EMS) developed and built in-house by e‑STORAGE's North American software team. e‑STORAGE will be responsible for the R1 grid connection studies, supply the hybrid power plant controller that coordinates the battery with the co-located solar farm, and lead the overall integration and commissioning of the hybrid project. The arrangement is backed by a 20-year long-term service agreement (LTSA), placing hardware, proprietary software, and long-term performance under a single accountable partner.

The project sits roughly 2.5 kilometers east of Muswellbrook, on land at a former coal mine within the Hunter-Central Coast Renewable Energy Zone. The location is significant: as the region's aging coal generators wind down toward retirement in the early 2030s, the dispatchable capacity they once provided must be replaced. Two-hour storage fills that gap directly, holding midday solar output and releasing it into the evening demand peak when supply from retiring thermal plants tightens.

Once operational, the system will support the long-term hybrid power purchase agreement OX2 has signed for the project, converting variable solar output into firm, contracted supply. By storing and dispatching solar energy on demand, the BESS strengthens grid reliability in a region transitioning away from coal and helps deliver firm renewable power to the communities in the Hunter Region.

Steve Symons, Vice President, OX2 Australia, said: "This battery storage system is what turns Muswellbrook into a true hybrid facility — pairing solar generation with storage so we can capture energy when the sun is shining and deliver it when the grid needs it most. It's a key step in providing firm, reliable renewable power to the Hunter region."

Jeff Roy, President of e‑STORAGE, said: "Australia's energy transition is being decided in regions like the Hunter, where storage now has to carry the load that retiring coal once did. We control this project from the cell through to our own energy management software and 20 years of service, which means OX2 has one partner accountable for how the system performs over its full life."

About Canadian Solar Inc.

Canadian Solar is one of the world's largest solar technology and renewable energy companies. Founded in 2001 and headquartered in Kitchener, Ontario, the Company is a leading manufacturer of solar photovoltaic modules; provider of solar energy and battery energy storage solutions; and developer, owner, and operator of utility-scale solar power and battery energy storage projects. Over the past 25 years, Canadian Solar has successfully delivered nearly 180 GW of premium-quality solar photovoltaic modules to customers across the world. Through its energy storage solutions business e-STORAGE, Canadian Solar has shipped over 23 GWh of battery energy storage solutions to global markets and had a contracted backlog of $3.5 billion as of June 30, 2026. Since entering the project development business in 2010, Canadian Solar has developed, built, and connected approximately 12.4 GWp of solar power projects and 6.4 GWh of battery energy storage projects globally. Its geographically diversified project development pipeline includes approximately 22 GWp of solar and 84 GWh of battery energy storage capacity in various stages of development. Canadian Solar is one of the most bankable companies in the solar and renewable energy industry, having been publicly listed on the NASDAQ since 2006. For additional information about the Company, follow Canadian Solar on LinkedIn or visit www.canadiansolar.com.

About e-STORAGE

e-STORAGE is a subsidiary of Canadian Solar and a leading company specializing in designing, manufacturing, and integrating battery energy storage systems for utility-scale applications. e-STORAGE offers proprietary battery energy storage systems (BESS) spanning battery cells, battery PACKs, power conversion systems (PCS), energy management systems (EMS) and system integration. It also provides comprehensive EPC services and full-lifecycle station operation and asset management, helping customers improve grid operations across the project lifecycle. For more info, please refer to the Media&PR section of www.csestorage.com and follow our LinkedIn page.

Safe Harbor/Forward-Looking Statements

Certain statements in this press release, including those regarding the Company's expected future shipment volumes, revenues, gross margins, and project sales are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially. These statements are made under the "Safe Harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as "may", "will", "expect", "anticipate", "future", "ongoing", "continue", "intend", "plan", "potential", "prospect", "guidance", "believe", "estimate", "is/are likely to" or similar expressions, the negative of these terms, or other comparable terminology. These forward-looking statements include, among other things, our expectations regarding global electricity demand and the adoption of solar and battery energy storage technologies; our growth strategies, future business performance, and financial condition; our transition to a long-term owner and operator of clean energy assets and expansion of project pipelines; our ability to monetize project portfolios, manage supply chain fluctuations, and respond to economic factors such as inflation and interest rates; our outlook on government incentives, trade measures, regulatory developments, and geopolitical risks; our expectations for project timelines, costs, and returns; competitive dynamics in solar and storage markets; our ability to execute supply chain, manufacturing, and operational initiatives; access to capital, debt obligations, and covenant compliance; relationships with key suppliers and customers; technological advancement and product quality; and risks related to intellectual property, litigation, and compliance with environmental and sustainability regulations. Other risks were described in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 20-F filed on April 10, 2026. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Investors should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today's date, unless otherwise stated, and Canadian Solar undertakes no duty to update such information, except as required under applicable law.

Canadian Solar Inc. Investor Relations Contact

Wina Huang

Investor Relations

Canadian Solar Inc.

[email protected]

e-STORAGE MEDIA CONTACT

[email protected] 

SOURCE Canadian Solar Inc.

Share this article

OceanaGold Provides Notice of Third Quarter 2026 Results and Conference Call

VANCOUVER, BC, Oct. 6, 2026 /PRNewswire/ -- OceanaGold Corporation (TSX: OGC) (NYSE: OGC) ("OceanaGold" or the "Company") will release its operational and financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The results will be made available on the Company's website at www.oceanagold.com.

Third Quarter 2026 Results Conference Call Details

Senior management will host a conference call and webcast to discuss the third quarter 2026 results on Thursday, November 5, 2026, at 10:00am ET (8:00am PT). To participate in the conference call, please use one of the following methods:

Webcast: https://app.webinar.net/YJvAQpM752D

Toll-free North America: 1-888-510-2154

International: 1-437-900-0527

If you are unable to attend the call, a recording will be made available on the Company's website.

About OceanaGold

OceanaGold is a global intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from our operations and delivering strong returns for our shareholders. We have a portfolio of four operating mines: the wholly-owned Haile Gold Mine in the United States of America; the wholly-owned Macraes and Waihi operations in New Zealand; and the 80%-owned Didipio Mine in the Philippines.

SOURCE OceanaGold Corporation

Share this article

1911 Gold's True North Resource Expansion Drilling Intersects up to 7.55 g/t Au over 5.00 m, Including 32.90 g/t Au over 0.50 m at the 710-711 Zone, and up to 21.20 g/t Au over 0.60 m at the 007 Zone

VANCOUVER, BC, Oct. 6, 2026 /PRNewswire/ -- 1911 Gold Corporation ("1911 Gold" or the "Company") (TSXV: AUMB) (OTCQX: AUMBF) (FRA: 2KY) is pleased to announce assay results from the underground resource expansion program at the Company's wholly-owned, operational and fully permitted True North Gold Project ("True North"), centrally located within the Company's 100%-owned Rice Lake Gold property, southeast Manitoba, Canada.

The latest assay results are from ten (10) diamond drill holes totaling 4,562 metres ("m"), completed as part of the underground resource expansion drill program. Drilling targeted potential extensions of the 710-711 and 007 zones outside the current Mineral Resource Estimate (the "2024 MRE"). Both target areas were tested from drill bays on Level 16 (720 m below surface, see Figure 1).

Highlights:

Drilling on the 710-711 vein system confirmed extensions of gold mineralization outside the 2024 MRE, with the following highlighted results:

UG16-26-079: Intersected 7.55 grams per tonne ("g/t") gold ("Au") over 5.00 m (at 277.00 m downhole depth), including 16.65 g/t Au over 1.20 m, including 32.90 g/t Au over 0.50 m, and 25.80 g/t Au over 0.50 m

UG16-26-060: Intersected 32.40 g/t Au over 1.10 m (at 197.80 m downhole depth)

UG16-26-079: Intersected 7.43 g/t Au over 1.50 m (at 245.90 m downhole depth), including 7.70 g/t Au over 1.00 m

UG16-26-054: Intersected 6.84 g/t Au over 2.50 m (at 325.00 m downhole depth), including 11.23 g/t Au over 1.30 m, including 16.60 g/t Au over 0.50 m

UG16-26-071: Intersected 3.42 g/t Au over 3.60 m (at 275.90 m downhole depth), including 4.75 g/t Au over 1.20 m

UG16-26-069: Intersected 3.51 g/t Au over 2.40 m (at 360.00 m downhole depth), including 5.94 g/t Au over 1.00 m

Drilling on the 007 vein system intersected the following highlighted results:

UG16-26-060: Intersected 21.20 g/t Au over 0.60 m (at 501.80 m downhole depth) and 9.92 g/t Au over 0.60 m (at 504.90 m downhole depth)

UG16-26-085: Intersected 7.65 g/t Au over 3.40 m (at 430.80 m downhole depth), including 19.60 g/t Au over 0.60 m

UG16-26-069: Intersected 3.51 g/t Au over 2.40 m (at 360.00 m downhole depth), including 5.94 g/t Au over 1.00 m

Shaun Heinrichs, President and CEO, stated, "We are pleased to have completed our current exploration drill program from both surface and underground, testing for new resources at True North. The latest high-grade drill results targeting the extensions of the 710-711 and 007 zones, coupled with the results previously released for the L10 Zone, confirm the potential to add new resources for the True North Gold Project, supporting our overall strategy to develop a district-scale project. These results will be incorporated into the updated mineral resource estimate currently underway."

The exploration drill program at True North, which commenced from surface in October 2024 and from underground in early October 2025, targeted new resources as well as expansion of known zones. The now-completed program comprised one hundred and three (103) surface drill holes totalling 28,475 m (including four drill holes that were abandoned before reaching target depth) and forty-six (46) underground drill holes totalling 17,346 m, targeting the new discoveries and resource expansion target areas.

The Company has commenced work on an updated resource estimate for True North which includes results from exploration drilling as well as the infill and delineation drill program, currently scheduled for completion in the fourth quarter of 2026 ("Q4/2026").

Table 1: Select Significant Drill Results – True North Underground Resource Expansion Drill Program (710-711 and 007 Zones)

The 710-711 Zone is hosted on the intersection of the Lower Basalt unit and the regional east-west steeply north-dipping L10 Shear Zone. The 007 Zone is hosted on the intersection of the Shoreline Basalt and the 007 Shear Zone, with both zones hosting gold-bearing mineralization associated with veins developed as northwest-trending extensional stockwork and breccia veins and east-west steeply north-dipping shear veins. Veining consists predominantly of quartz with accessory ankerite and albite, with sericite-pyrite and chlorite occurring as veinlets and pervasive alteration halos. Gold occurs with minor pyrite and as free native gold.

The 007 Shear Zone hosts a series of mineralized veins, which are the primary targets of the current resource expansion program at 007 and 710-711 zones. The 007 Shear Zone also hosts the new Shore target, recently the focus of surface and underground exploration drilling and hosted within the San Antonio Gabbro unit located approximately 500 m to the west. The L10 Shear hosts the new SAM SE Target hosted within the San Antonio Gabbro, approximately 500 m to the west of 710-711.

Given the proximity of the lower extent of the 007 Zone to the 710-711 Zone, drilling on both targets was conducted from Level 16 underground.

710-711 Zone Resource Expansion Drilling: Discussion of Results

Five (5) drill holes (UG16-26-054, 071, 075, 078 and 079) tested extensions of gold mineralization above the 710-711 Zone resource limit, all successfully intercepting gold-mineralized quartz-carbonate veins up-plunge. Two (2) additional drill holes (UG16-26-056 and 57) tested extensions of gold mineralization to the east and returned no significant results.

007 Zone Resource Expansion Drilling: Discussion of Results

Three (3) drill holes (UG16-26-060, 069, and 0085) tested extensions of gold mineralization below the 007 Zone resource limit, all successfully intercepting gold-mineralized quartz-carbonate veins down-plunge.

The latest results have confirmed the potential to define additional gold mineralization in multiple veins outside the 2024 MRE boundary. Gold mineralization was extended by 60 m from the upper resource limit of the 710-711 Zone and over a strike length of 115 m. Gold mineralization was extended by 120 m below the 007 Zone and over a strike length of 150 m, highlighting the potential to further increase and extend mineralization with additional drilling.

Next Steps

1911 Gold has now commenced a mineral resource update for True North expected in Q4/2026, which will include the three discoveries, San Antonio West, San Antonio Southeast, and Shore, as well as the extensions of current resources from the L10, 710-711, 007 and Hinge zones.

Exploration drilling from surface and underground will recommence once results from the recently completed program have been assessed and reviewed, supported by positive results highlighting key areas for follow-up.

The Company's ongoing infill and delineation drill program on areas contemplated for test mining and the early years of the Preliminary Economic Assessment mine schedule is being conducted from underground with three (3) drill rigs: two (2) on Level 16 and one from the Hinge decline. A fourth underground drill rig will be mobilized upon completion of rehabilitation on Level 26.

Table 2: True North Drill Hole Details (UTM NAD83 Zone 15)

Qualified Person Statement

The scientific and technical information in this news release has been reviewed and approved by Mr. Michele Della Libera, P.Geo, Vice-President Exploration of 1911 Gold Corporation, who is a "Qualified Person" as defined under NI 43-101.

Quality Assurance/Quality Controls (QA/QC)

Oriented core samples are collected by sawing the drill core in half along the axis, with one-half sampled, placed in plastic sample bags, labelled, sealed, and the other half retained for future reference. Batches are shipped to Activation Laboratories Ltd. (Actlabs), in Thunder Bay, Ontario, for sample preparation and analysis. Samples are dried, crushed to 2 mm and a 1 kg split is pulverized to -200 mesh. Gold analysis is completed by fire assay with an atomic absorption finish on 50 grams of prepared pulp. Samples returning values equal or greater to 10.00 g/t are reanalyzed by fire assay with a gravimetric finish. Total gold analysis (Screen Metallic Sieve) is conducted on highly mineralized samples or the presence of visible gold. Certified gold reference material samples are inserted every 20 samples and blank samples at intervals of one in every 50 samples, with additional blanks inserted after samples hosting visible gold. Repeat third-party gold analyses for 5% of all submitted sample pulps are analyzed at ALS-Chemex Laboratory, North Vancouver, Canada.

About 1911 Gold Corporation

1911 Gold is an advanced gold explorer and developer focused on its 100%-owned True North Gold Project in the Archean Rice Lake Greenstone Belt in Manitoba, Canada. The Company controls a large, highly prospective ~62,000-hectare land package with numerous past-producing gold operations within trucking distance of the fully built and permitted True North mine and mill complex. 1911 Gold is positioning itself to make a decision on restarting operations in the future and offers a unique investment opportunity with significant exploration upside. The strategy is to build a district-scale gold mining operation around centralized, readily expandable infrastructure to support a socially and environmentally responsible, long-term mining operation with low development risk and a growing mineral resource base.

1911 Gold's True North complex and exploration land package are located in an area of importance to Indigenous Nations, communities, and rights-holders. 1911 Gold looks forward to maintaining open, cooperative, respectful, and meaningful communication while also engaging with other stakeholders, to foster mutually beneficial working relationships.

Comprehensive power modes, enhanced stamina metrics, a ComfortFit Fabric Band and Garmin Epic help endurance athletes and multiday adventurers train, race and explore even farther

OLATHE, Kan., Oct. 6, 2026 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Enduro™ 4, its longest-lasting GPS smartwatch with solar charging, which includes dynamic features and capabilities to take endurance enthusiasts farther on their next expedition. Utilizing an energy-efficient 1.4" MIP display in combination with a solar lens, Enduro 4 has up to 320 hours of battery life in activity mode1 or up to 90 days of battery life in smartwatch mode2. It also leverages innovative updates like grade-adjusted pace-based workout targets, grade-adjusted rolling pace, stamina zones, stamina curve and Garmin Epic multiday activity logging.

"As interest and participation in ultra-endurance activities continue to grow, Enduro 4 is designed for athletes and adventurers who want gear they can trust to perform through every mile, every climb and every challenge. Intuitive features like comprehensive power modes make the most of the long-lasting battery life, while grade-adjusted metrics add a new dimension to preparing for hilly or mountainous terrain."

—Susan Lyman, Garmin Vice President of Consumer Sales and Marketing

Grade-adjusted features, stamina metrics and more

In addition to 100+ activity profiles, Enduro 4 introduces new capabilities to the Enduro line, optimized for trail runners, multiday hikers and backpackers, and endurance athletes.

- Comprehensive power modes provide preset options to optimize battery life and performance based on the needs of the user. Configurations include Max Accuracy, which offers full-feature tracking for shorter efforts, and Max Battery, ideal for extended activity recording (up to 320 hours with solar charging).

- Grade-adjusted pace-based workout targets help athletes maintain the right effort range on hilly terrain, while grade-adjusted rolling pace provides a real-time view of pace over varying terrain.

- Stamina zones show athletes how their stamina impacts an activity, and stamina curve helps users understand how their endurance changes over time based on fitness and training history.

- With 50% more RAM than Enduro 3 and a more powerful, updated map engine, navigation is easier than ever with 30% faster panning and a smoother, more intuitive map interface for built-in routable maps. Perspective view provides more detail, both close-up and further away, allowing users to better anticipate what comes next.

- Garmin Epic allows athletes to combine multiple activities into one cohesive story in Garmin Connect™. Activities can be grouped together over days, weeks or months to create an "Epic", which enables users to add photos and share with family and friends, as well as see health and performance data aggregated during that period.

- Enhanced rowing tools provide additional training insights like VO2 max and power curve for indoor rowing activities, while expanded rucking features let users adjust pack weight during an activity and set target metrics like calories burned.

Premium design for maximum versatility

Enduro 4 weighs in at an incredible 66 grams, making it one of the lightest ultraperformance smartwatches on the market. With a 51mm case, Power Sapphire™ scratch-resistant lens, titanium bezel and lightweight fiber-reinforced polymer case, it is built for the demands of the longest races and most taxing adventures, remaining remarkably light on the wrist. An integrated LED flashlight includes both white and red-light options, while a 10 ATM water resistance rating enables confident use in challenging environments.

New to Enduro 4, the ComfortFit Fabric Band combines exceptional comfort, durability and moisture-wicking performance with QuickFit™ functionality, making adjustments and swapping bands even simpler. 64 GB of memory gives users more room for onboard maps, music and data, making it easier to stay prepared for extended adventures away from home.

Available now, Enduro 4 has a suggested retail price of $899.99. Learn more at Garmin.com.

Engineered on the inside for life on the outside, Garmin products have revolutionized life for adventurers, athletes, off-road explorers, road warriors and outdoor enthusiasts everywhere. Committed to developing products that enhance experiences, enrich lives and help provide peace of mind, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garminoutdoor on social, or follow our blog.

1 Assumes continuous use for entire period in 50,000 lux conditions and typical use with activity mode (extended battery) selected

2 Assumes all-day wear with 3 hours per day outside in 50,000 lux conditions

About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark and Enduro, Garmin Connect, Power Sapphire and QuickFit are trademarks of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:

This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 27, 2025, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). Copies of such Form 10-K are available at https://www.garmin.com/en-US/investors/sec/. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

MEDIA CONTACTS:

Elliott Scott

913-397-8200

[email protected]

SOURCE Garmin International, Inc.

Share this article

Veeva DQS Cleans Data for More Than 1 Million Subjects Across Over 1,000 Studies

Automates data reconciliation, saving clinical teams significant cost, time, and effort

BARCELONA, Spain, Oct. 6, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Veeva DQS (Data Quality System) has aggregated and cleaned data for more than 1 million subjects in more than 1,000 studies to accelerate the delivery of analysis-ready data and trial insights. With more than 500,000 automated queries, Veeva DQS has saved thousands of hours in data reconciliation for sites and sponsors.

"One key area for us is handling the increasing volume of data generated from our growing number of clinical trials," said Ibrahim Kamstrup-Akkaoui, vice president at Novo. "Veeva DQS can help us manage, format, clean, and prepare this data for submission more efficiently."

Veeva DQS enables next-generation clinical data management with advancements essential for adopting the risk-based strategies recommended in regulatory guidelines, including ICH E6(R3). With innovations coming in Veeva DQS, clinical teams can:

- Gain high-quality data faster: Veeva DQS automates data workflows, classifies and visualizes critical data, and drives the orchestration of risk-based actions across the clinical ecosystem while eliminating manual data reconciliation.

- Enable risk-based quality management (RBQM): Automated data exchange between Veeva DQS and Veeva CTMS streamlines risk-based monitoring by instantly alerting clinical operations teams to key data changes, like protocol deviations, and allowing clinical data teams to calculate, track, and action key risk indicators (KRIs).

- Classify with data- and user-aware AI: Veeva DQS embeds AI to speed up the classification of study data and understand its purpose and criticality. This allows the system to generate items, like reports, listings, or test scripts, and deliver custom user experiences and workflows based on role.

"With increasing data sources and growing protocol complexity, sponsors and CROs are using Veeva DQS to automate data workflows at scale across studies of all sizes," said Pavel Burmenko, lead, Veeva DQS strategy. "Veeva DQS is ushering in next-generation data management, a new level of clinical data innovation that orchestrates risk-based reviews and elevates the role of data managers toward strategic partners."

Recently announced, Veeva Study Builder Agent configures Veeva EDC and Veeva DQS directly from a study protocol for faster and more consistent study builds. Learn more about Study Builder Agent, the SCDM Innovation Award winning Veeva DQS, and how biopharmas are driving clinical data innovation at Veeva R&D and Quality Summit, Oct. 20-21 in Boston. The event is open exclusively to life sciences industry professionals.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-Looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker

Veeva Systems

+49-695-095-5486

[email protected]

Share this article

TORONTO, Oct. 6, 2026 /PRNewswire/ -- Aclara Resources Inc. ("Aclara" or the "Company") (TSX: ARA) is pleased to announce it is expanding the scope of Project Dynamo, its planned rare earth separation facility in Louisiana, to incorporate separation capabilities for yttrium ("Y"), gadolinium ("Gd") and samarium ("Sm"), in addition to the previously planned production of neodymium-praseodymium ("NdPr"), dysprosium ("Dy") and terbium ("Tb").

As the first stage of this expansion, Aclara, through its wholly-owned subsidiary Aclara Technologies Inc., has commenced the installation of additional solvent extraction ("SX") circuits at its rare earth separation demonstration plant located at Virginia Tech Corporate Research Center in Blacksburg, Virginia. The new circuits are being designed to demonstrate the separation of Y, Gd and Sm using feedstock representative of the Super-Pure Rare Earth Carbonate ("SPREC") expected to be produced from Aclara's ionic clay deposits in Chile and Brazil.

Work at the demonstration plant is already underway. Equipment for the new Y separation circuit has arrived at the Virginia Tech facility and is expected to be installed and commissioned over the coming weeks, with Gd and Sm circuits expected to follow.

To support the expanded program, Aclara has doubled the physical footprint of its demonstration plant and is planning to approximately double the number of technical personnel supporting the facility.

Ramon Barua, Chief Executive Officer of Aclara, commented:

"The expansion of Project Dynamo represents an important advancement of Aclara's strategy. In addition to building a supply chain for the rare earths required for permanent magnets, we are expanding into materials that are becoming critical to power generation, aerospace applications -including aircraft jet engines- and the infrastructure supporting artificial intelligence."

"Yttrium is a particularly compelling opportunity. Approximately 50% of the rare earth composition of our Penco Project and 30% of our Carina Project is yttrium, giving Aclara a differentiated resource position in a market where Western supply remains highly dependent on imports. Penco has received its environmental approval and is positioned to advance toward construction, subject to securing the required financing."

"The rapid growth of AI and data centers is driving significant investment in power generation infrastructure, including gas turbines, where yttrium plays an important role in high-temperature applications. By combining our resource base with separation capabilities in the United States, we believe Aclara can become an important supplier into these strategic markets."

Expanding Project Dynamo

Project Dynamo was originally designed to separate NdPr, Dy and Tb. The planned expansion will add dedicated separation capabilities for Y, Gd and Sm, broadening the range of high-purity rare earth products Aclara intends to produce in the United States.

To incorporate the expanded product scope, Aclara is modifying the basic engineering of Project Dynamo to include the additional separation circuits in the industrial-scale facility in Louisiana. As part of this expansion, the number of mixer-settlers in the solvent extraction process is expected to increase from approximately 340 to 478, representing a significant expansion of the plant's separation capacity and complexity.

The expansion is expected to create two complementary rare earth platforms:

- Magnetic rare earths: NdPr, Dy, Tb and Sm, serving applications including e-mobility and robotics;

- Non-magnetic rare earths: Y and Gd, serving applications across power generation, aerospace applications -including aircraft jet engines- and other high-performance technologies.

Project Dynamo has secured its State Air Permit from the Louisiana Department of Environmental Quality, and basic engineering for the facility is in its final stages. Aclara is targeting groundbreaking in the first quarter of 2027, subject to securing the required financing.

Yttrium: A Strategic Growth Opportunity

Aclara believes yttrium represents a significant new growth opportunity.

The rapid expansion of AI and cloud infrastructure is driving substantial investment in data centers and associated power generation capacity. Gas turbines are expected to play an important role in supporting this growth, and yttrium is used in advanced high-temperature materials required in turbine applications.

Aclara believes it is particularly well positioned because yttrium represents a significant component of its ionic clay resource base. Based on the current technical reports for the Carina Project and Penco Module, Aclara expects its mineral projects to have the potential to produce SPREC containing approximately 1,400 tonnes of yttrium per year at full production.

The Company is engaged in preliminary discussions with potential customers regarding future supply of yttrium and other rare earth products from Project Dynamo; no definitive offtake agreement have been entered into.

Collaboration with Virginia Tech and Argonne National Laboratory

Aclara's U.S. separation development program combines the Company's proprietary rare earth processing technology with the capabilities of Virginia Tech and Argonne National Laboratory ("Argonne").

Virginia Tech hosts Aclara's demonstration plant in Blacksburg, where operating data is generated to demonstrate and optimize the Company's separation process ahead of commercial-scale deployment at Project Dynamo.

The collaboration with Virginia Tech is also an important component of Aclara's workforce development strategy. Rebuilding rare earth industrialization and processing capabilities in the United States will require experienced engineers, chemists and plant operators with direct operating experience in rare earth separation.

Aclara is using the demonstration plant as a training platform for the technical workforce that will ultimately support Project Dynamo. Engineers, chemists and operators are expected to gain up to two years of hands-on operating experience at the Virginia Tech facility before the Louisiana plant enters production, which Aclara expects to provide a trained and experienced workforce to support a faster and lower-risk ramp-up of the commercial facility.

Aclara is also collaborating with Argonne under a Cooperative Research and Development Agreement to develop an AI-enabled digital twin of the separation process using operational data from the Virginia Tech facility and Argonne's SolventX modeling platform.

Together, the Virginia Tech and Argonne collaborations are designed to support both the technical optimization of the process and the development of the people and operating capabilities required to scale rare earth separation in the United States.

About Aclara

Aclara Resources Inc. (TSX: ARA), a Toronto Stock Exchange listed company, is focused on building a vertically integrated supply chain for rare earth alloys used in permanent magnets, as well as high-purity rare earth oxides, including yttrium and gadolinium, for power generation, aerospace and other high-performance applications. This strategy is supported by Aclara's development of rare earth mineral resources hosted in ionic clay deposits, which contain high concentrations of the scarce heavy rare earths, providing the Company with a long-term, reliable source of these critical materials. The Company's rare earth mineral resource development projects include the Carina Project in the State of Goiás, Brazil as its flagship project and the Penco Module in the Biobío Region of Chile. Both projects feature Aclara's patented technology named Circular Mineral Harvesting, which offers a sustainable and energy-efficient extraction process for rare earths from ionic clay deposits. The Circular Mineral Harvesting process has been designed to minimize the water consumption and overall environmental impact through recycling and circular economy principles. Through its wholly-owned subsidiary, Aclara Technologies Inc., the Company is further enhancing its product value by developing a rare earth separation plant in the United States. This facility will process mixed rare earth carbonates sourced from Aclara's mineral resource projects, separating them into pure individual rare earth oxides. Additionally, Aclara through a joint venture with CAP, is advancing its alloy-making capabilities to convert these refined oxides into the alloys needed for fabricating permanent magnets. This joint venture leverages CAP's extensive expertise in metal refining and special ferro-alloyed steels. Beyond the Carina Project and the Penco Module, Aclara is committed to expanding its mineral resource portfolio by exploring greenfield opportunities and further developing projects within its existing concessions in Brazil, Chile, and Peru, aiming to increase future production of heavy rare earths.

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735

Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated

SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory oral maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. The trial announced today is the second in a two-part maintenance study initiated in 2025. Positive top-line results were recently announced from Part 1 of this study, which evaluated various subcutaneous dosing regimens for their potential to maintain the initial weight loss achieved with weekly subcutaneous dosing. Part 2 of the study is designed to explore the potential of various VK2735 oral tablet dosing regimens as well as additional subcutaneous dosing regimens to maintain the initial weight loss achieved from weekly subcutaneous dosing.

The maintenance dosing study is a randomized, double-blind, placebo-controlled trial in approximately 195 adults with obesity (BMI ≥30 kg/m2) who are otherwise healthy. As in Part 1 of the study, all participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, weekly oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. The study objectives are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints will assess changes in body weight from baseline and from Week 21 to the end of the study at Week 33.

"Our recent top-line results from Part 1 of this study demonstrated the potency and differentiated profile of VK2735 in the setting of both weight loss induction and potentially longer-term maintenance. We are eager to continue this study with the initiation of Part 2, which will explore multiple regimens, both oral and subcutaneous, with the potential to provide greater optionality and flexibility to best align with a patient's individual weight loss journey," said Brian Lian, Ph.D., chief executive officer of Viking. "Adherence to therapy is critical to achieving the long-term benefits of weight loss, including reduction of cardiovascular risk, improved physical function, and enhanced quality of life. We believe flexibility and optionality are key to increasing adherence to treatment and improving long-term weight management - from induction to maintenance. We were pleased to report positive results from our recent subcutaneous maintenance study and are excited by the potential to validate additional maintenance regimens as well. In doing so, we expect to offer patients and their clinicians a broad range of highly effective and convenient tools to achieve personalized weight loss goals. We look forward to reporting the results from Part 2 of this study in 2027."

In addition to the maintenance dosing study, Viking is currently conducting two Phase 3 studies evaluating subcutaneous VK2735 (VANQUISH-1 and VANQUISH-2). These trials are randomized, double-blind, placebo-controlled, multicenter trials designed to assess the efficacy and safety of subcutaneous VK2735 dosed weekly for 78 weeks. The VANQUISH-1 study is fully enrolled with approximately 4,500 adults who do not have type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is also fully enrolled with approximately 1,000 adults with type 2 diabetes who have obesity or are overweight. Patients in both trials are being randomized to one of four weekly treatment arms: VK2735 7.5 mg; VK2735 12.5 mg; VK2735 17.5 mg; and placebo.

About GLP-1 and Dual GLP-1/GIP Agonists

Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Ozempic®, Rybelsus®, and Wegovy®. More recently, research efforts have explored the potential co-activation of the glucose-dependent insulinotropic peptide (GIP) receptor as a means of enhancing the therapeutic benefits of GLP-1 receptor activation. Tirzepatide is a dual GLP-1/GIP receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various dosage strengths and forms as Mounjaro® and Zepbound®.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance.These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK0214, VK2809, and the company's other incretin receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission, including Viking's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings.These forward-looking statements speak only as of the date hereof.Viking disclaims any obligation to update these forward-looking statements except as required by law.

SOURCE Viking Therapeutics, Inc.

Share this article

STOKE Shoes Welcomes Footwear Industry Veteran Dave Powers as Advisor and Investor

Former Deckers Brands President & CEO and HOKA growth leader joins STOKE as the brand tackles one of footwear's biggest fit problems.

GEORGES MILLS, N.H., Oct. 6, 2026 /PRNewswire/ -- STOKE Shoes, the footwear brand focused on delivering exceptional comfort and fit for everyday wear, today announced that Dave Powers, former President and CEO of Deckers Brands, has joined the company as an advisor and investor.

Powers brings more than four decades of experience building and scaling global footwear and retail businesses, including nearly 13 years at Deckers Brands, where he served as President and CEO from 2016 to 2024. During his tenure, Powers helped lead Deckers through a period of significant growth, including the transformation of HOKA from a niche running brand into a billion-dollar-plus global business. Deckers reported record fiscal 2024 revenue of $4.29 billion under his leadership.

Now, Powers is bringing that experience to Stoke Shoes, a brand addressing a significant but often overlooked problem in footwear: fit.

According to the 2026 Volumental Foot Scan, approximately 76% of men in the U.S. have wide feet, highlighting a significant disconnect between the shape of consumers' feet and the footwear they typically wear. For Stoke, that gap represents an opportunity to rethink how men's footwear is designed around the actual shape of the foot.

"Dave is one of those rare people who has an incredible track record, but is also just a genuinely good dude," said Rick Blackshaw, Co-Founder of Stoke Shoes. "We're incredibly fortunate to have him as an advisor and investor. He knows footwear, he knows how to build brands, and he knows what it takes to scale a business. Even better, there's a personal connection here as CMO Ian Stewart and I first crossed paths with Dave during our time at Converse, so bringing him into STOKE feels like a natural continuation of a relationship that started years ago."

During his time at Deckers, Powers helped create more than $10 billion in shareholder value, while overseeing a period of substantial brand, revenue, and market-capitalization growth. Deckers' own announcement of Powers' retirement credited him with helping build the company into an industry leader and "dramatically increasing shareholder value" during his tenure.

Prior to Deckers, Powers spent four years at Converse, a Nike brand, as Vice President of Global Direct-to-Consumer and Licensed Retail, where he led international DTC expansion and served as part of the Nike retail leadership team. He previously held leadership roles at Timberland and spent a decade at Gap Inc.

"I've spent my career around footwear and STOKE immediately stood out to me because the team is solving a real consumer problem," said Dave Powers. "The opportunity to build a brand around comfort, fit and how people actually live is compelling. I know what it takes to build great footwear brands, and I believe Stoke has the product, the team and the opportunity to do something meaningful in the market. I'm excited to be part of the journey."

As an advisor and investor, Powers will work closely with Stoke's leadership team on brand strategy, product development, retail expansion, distribution and long-term growth.

"Stoke isn't trying to make another shoe and put a logo on it," added Blackshaw. "We're focused on making footwear that actually works for the way people live, and that starts with understanding the foot. Having someone with Dave's experience, perspective and network in our corner gives us an incredible resource as we build the company."

Based in Santa Barbara, Powers holds a B.A. in Marketing from Northeastern University.

About STOKE Shoes

STOKE Shoes is a performance-lifestyle brand engineered for the 97 million all-American men with wide feet overlooked by the athletic footwear industry. Founded by Rick Blackshaw in 2025, Stoke builds shoes that match how real men live; with more room, more cushioning, and more honesty. The company is headquartered in New Hampshire with global manufacturing partners. For more information, visit [www.stokeshoes.com] and follow Stoke Shoes on social media.

Media Contact:

Bethany Willetts | [email protected] 

SOURCE STOKE Shoes

Share this article